fludarabine has been researched along with melphalan in 257 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.56) | 18.2507 |
| 2000's | 106 (41.25) | 29.6817 |
| 2010's | 116 (45.14) | 24.3611 |
| 2020's | 31 (12.06) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Bosanquet, AG; Catovsky, D; Crotty, GM; McCann, SR; Mills, MJ | 1 |
| Byrnes, JJ; Frankfurt, OS; Villa, L | 1 |
| Alvegård, TA; Békássy, AN; Chan, KW; Ha, CS; Nunez, C; Sallerfors, B | 1 |
| del Potro Gómez, E; Morales Sanz, D | 1 |
| Chakrabarti, S; Chakraverty, RK; Chopra, R; de Elvira, MC; Devereux, S; Goldstone, AH; Hale, G; Kottaridis, PD; Linch, DC; Mackinnon, S; Mahendra, P; Marsh, JC; Milligan, DW; Morgan, GJ; Peggs, K; Pettengell, R; Robinson, S; Schey, S; Verfuerth, S; Waldmann, H; Williams, CD | 1 |
| Acholonu, S; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, RE; Cohen, A; Giralt, S; Hagemeister, F; Khouri, I; Körbling, MJ; Manning, J; Mclaughlin, P; Romaguera, J; Sarris, A; Ueno, NT | 1 |
| Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M | 1 |
| Anderlini, P; Andersson, BS; Andreeff, M; Braunschweig, I; Bruton, J; Champlin, R; Claxton, D; Cohen, A; Davis, M; Donato, M; Gajewski, J; Giralt, S; Ippolitti, C; Khouri, I; Kornblau, S; Molldrem, J; Przepiorka, D; Thall, PF; Ueno, NT; Wang, X | 1 |
| Bryon, RJ; Chakrabarti, S; Griffiths, MJ; Handa, SK; Milligan, DW | 1 |
| Grigg, AP; Ritchie, DS; Roberts, AW; Seymour, JF; Szer, J | 1 |
| Amin, K; Chen, YH; Devine, H; Devine, SM; Huml, M; Jessop, E; Maningo, M; Peace, D; Sanborn, R; Stock, W; Thomason, D; van Besien, K; Wickrema, A; Yassine, M | 1 |
| Kashyap, A; Snowden, J | 1 |
| Branson, K; Chakrabarti, S; Chakraverty, R; Chopra, R; Craddock, C; Geary, J; Goldstone, AH; Hale, G; Hunter, A; Kottaridis, PD; Linch, DC; Mackinnon, S; Mahendra, P; Milligan, DW; Parker, A; Peggs, K; Thuraisundaram, D; Verfuerth, S; Waldmann, H; Williams, CD; Yong, K | 1 |
| Bradlow, BA; Chen, YH; Devine, SM; Hoffman, R; Huml, M; Jessop, E; Maynard, V; Peace, D; Shah, R; Stock, W; Thomason, D; van Besien, K; Verma, A | 1 |
| Chakrabarti, S; Chakraverty, RK; Chopra, R; Devereux, S; Goldstone, AH; Hale, G; Kottaridis, PD; Linch, DC; MacKinnon, S; Mahendra, P; Marsh, JC; Milligan, DW; Morgan, GJ; Peggs, K; Pettengell, R; Robinson, S; Ruiz de Elvira, MC; Schey, S; Verfuerth, S; Waldmann, H; Williams, CD | 1 |
| Aleman, A; Alexanian, R; Anagnostopoulos, A; Anderlini, P; Champlin, R; Donato, M; Gajewski, J; Giralt, S; Khouri, I; Korbling, M; Molldrem, J; Ueno, NT; Weber, D | 1 |
| Afanasyev, BV; Anagnostopoulos, A; Andreeff, M; Champlin, RE; Mikhailova, N; O'Brien, S; Pankratova, OS; Rondón, G; Semenova, EV; Ueno, NT; Zaritskey, AY; Zoubarovskaya, LS | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Caballero, D; Chopra, R; Craddock, C; García-Conde, J; Goldstone, AH; Hunter, A; Kottaridis, PD; Leon, A; Linch, DC; Mackinnon, S; Martino, R; Milligan, DW; Parker, A; Pérez-Simón, JA; San Miguel, JF; Schey, S; Sierra, J; Sureda, A; Urbano-Ispizua, A; Yong, K | 1 |
| Ayuk, F; Fehse, B; Kiehl, M; Kröger, N; Nagler, A; Renges, H; Sayer, HG; Schmitz, N; Schwerdtfeger, R; Wittkowsky, G; Zabelina, T; Zander, AR | 1 |
| Belohradsky, BH; Blanche, S; Bordigoni, P; Cant, A; Di Bartolomeo, P; Fischer, A; Flood, T; Gungor, T; Landais, P; Müller, S; Nagler, A; Ozsahin, H; Passwell, JH; Porta, F; Seger, RA; Slavin, S; Wulffraat, N; Zintl, F | 1 |
| Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G | 1 |
| Bellosillo, B; Casado, FJ; Colomer, D; Gil, J; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M | 1 |
| Hansz, J | 1 |
| Abonour, R; Logan, TF; Nelson, RP | 1 |
| Caenazzo, L; Calore, E; Cesaro, S; De Silvestro, G; Destro, R; Gazzola, MV; Marson, P; Messina, C; Pillon, M; Varotto, S; Zanesco, L | 1 |
| Chakrabarti, S | 1 |
| Bertz, H; Finke, J; Potthoff, K | 1 |
| Durrant, S; Grigg, AP; Morton, J; Ritchie, DS; Roberts, AW; Shuttleworth, P; Szer, J | 1 |
| Anderlini, P; Booser, DJ; Champlin, RE; Cheng, YC; Couriel, DR; de Lima, MJ; Gajewski, JL; Giralt, SA; Hortobagyi, GN; Hosing, C; Jonasch, E; Khouri, IF; Pagliaro, LC; Rondón, G; Tannir, NM; Ueno, NT | 1 |
| Amin, K; Chen, YH; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sossman, J; Stock, W; Van Besien, K; Wickrema, A; Yassine, M | 1 |
| Miyakoshi, S | 1 |
| Beyer, J; Claviez, A; Dörffel, W; Dreger, P; Ehninger, G; Klingebiel, T; Nürnberger, W; Schmitz, N; Suttorp, M | 1 |
| Champlin, RE; Donato, ML; Gershenson, DM; Levenback, C; McMeekin, S | 1 |
| Al-Kadhimi, Z; Angelopoulou, M; Cohen, S; Falk, PM; Forman, SJ; Fung, HC; Kogut, N; Krishnan, AY; Nademanee, A; O'Donnell, MR; Parker, P; Popplewell, L; Rodriguez, R; Sahebi, F; Schriber, J; Senitzer, D; Slovak, M; Smith, D; Snyder, DS; Somlo, G; Spielberger, R; Stein, A | 1 |
| Anastasi, J; Larson, R; Odenike, T; Smith, S; Stock, W; Thirman, M; Van Besien, K | 1 |
| Avivi, I; Chakrabarti, S; Dogan, A; Goldstone, AH; Kottaridis, P; Kyriaku, C; Linch, D; Mackinnon, S; Milligan, DW | 1 |
| Barnardo, M; Campbell, AJ; Collins, GP; Eagleton, H; Jones, J; Keen-Mcguire, A; Littlewood, TJ; Malladi, RK; Miller, E; Morgenstern, G; Norton, AE; Peniket, AJ; Samol, J | 1 |
| Byun, JH; Hong, YS; Kim, CC; Lee, JW; Lee, MA; Min, WS; Park, JN; Roh, SY; Shim, BY; Song, CW | 1 |
| Alegre, A; Ayuk, F; Beyer, J; Brand, R; Fauser, A; Kiehl, M; Klingemann, H; Kröger, N; Leon, A; Martino, R; Myint, H; Nagler, A; Perez-Simon, JA; San Miguel, JF; Sayer, HG; Schwerdtfeger, R; Shimoni, A; Tomas, JF; Zabelina, T; Zander, AR | 1 |
| Aleskog, A; Höglund, M; Larsson, R; Laurell, A; Lindhagen, E; Nilsson, K; Nygren, P; Roos, G; Rosenquist, R; Sundström, C; Thunberg, U; Tobin, G | 1 |
| Beltrami, G; Carella, AM; Corsetti, MT; Musto, P; Scalzulli, P | 1 |
| Kato, Y; Kohno, A; Morishita, Y; Narimatsu, H; Ozeki, K; Saito, S; Shimada, K | 1 |
| Hartwig, UF; Herr, W; Huber, C; Kolbe, K; Kreiter, S; Meyer, RG; Schneider, PM; Ullmann, AJ; Wehler, T; Winkelmann, N | 1 |
| Benesch, M; Dornbusch, HJ; Lackner, H; Schwinger, W; Sovinz, P; Urban, C | 1 |
| Ayuk, F; Beyer, J; Binder, T; Bornhäuser, M; Eiermann, T; Iacobelli, S; Kiehl, M; Kröger, N; Madrigal, A; Marks, DI; Nagler, A; Peggs, K; Sayer, HG; Schwerdtfeger, R; Shaw, B; Shimoni, A; Zabelina, T; Zander, AR | 1 |
| Attarbaschi, A; Gadner, H; Grois, N; Holter, W; Matthes-Martin, S; Minkov, M; Ouachee, M; Steiner, M; Unger, E; Vormoor, J; Wawer, A; Woessmann, W | 1 |
| Artz, A; Bennett, D; Cao, D; Casey, B; Daugherty, C; Del Cerro, P; Godley, L; Jones, D; Larson, RA; Odenike, O; Rich, S; Smith, S; Stock, W; Thirman, M; van Besien, K; Wickrema, A; Zimmerman, T | 1 |
| Blumstein, N; Buchmann, I; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Kotzerke, J; Neumaier, B; Reske, SN; Ringhoffer, M; Schauwecker, P; Stilgenbauer, S; von Harsdorf, S; Wiesneth, M; Zenz, T | 1 |
| Begum, G; Chopra, R; Cook, G; Cook, M; Craddock, C; Goldstone, A; Hale, G; Hunter, A; Jackson, G; Khwaja, A; Littlewood, T; Mackinnon, S; Mahendra, P; Marsh, J; Milligan, D; Parker, A; Peggs, K; Peniket, A; Russell, N; Tauro, S | 1 |
| Rzepecki, P; Sarosiek, T; Szczylik, C | 1 |
| Champlin, RC; Chan, KW; Choroszy, M; Ha, CS; Madden, R; Mahajan, A; Mullen, CA; Petropoulos, D; Worth, LL | 1 |
| Inamoto, Y; Kodera, Y; Kuwatsuka, Y; Miyamura, K; Oba, T; Tokunaga, M; Tsujimura, A | 1 |
| Imamura, T; Kadota, J; Kikuchi, H; Kohno, K; Ogata, M; Ohtsuka, E; Tomo, T | 1 |
| Inamoto, Y; Kasai, M; Kodera, Y; Kuwatsuka, Y; Miyamura, K; Murata, M; Naoe, T; Oba, T; Terakura, S; Tokunaga, M; Tsujimura, A | 1 |
| Goh, YT; Hwang, WY; Koh, BC; Koh, LP; Linn, YC; Loh, SM; Ratnagopal, P; Tan, HC | 1 |
| Cantu-Rodríguez, O; Gomez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, H; Herrera-Garza, J; Jaime-Pérez, J; Mancias-Guerra, C | 1 |
| Coleman, M; Feldman, EJ; Harpel, J; Leonard, JP; Roboz, GJ; Schuster, MW; Shore, T; Silver, RT | 1 |
| Brugiatelli, M; Callea, V; Console, G; Iacopino, P; Irrera, G; Martino, M; Morabito, F; Musolino, C; Piro, E; Praticò, G; Quartarone, E; Stelitano, C | 1 |
| Anderlini, P; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Hosing, C; Khouri, IF; Korbling, M; Lekakis, L; Martin, T; Shpall, EJ | 1 |
| Fujii, H; Goto, H; Ikuta, K; Isaki, S; Kajiwara, R; Kuroki, F; Takahashi, H; Yanagimachi, M; Yokota, S | 1 |
| Beri, R; Chen, HY; Chunduri, S; Dobogai, LC; Hoffman, R; Jessop, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y | 1 |
| Dalal, J; Davies, SM; Filipovich, A; Kamani, N; Lee, SM; Rao, A; Shenoy, S | 1 |
| Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K | 1 |
| Forman, SJ; Kogut, N; Krishnan, A; Nademanee, A; Nakamura, R; Patane, K; Popplewell, L; Rodriguez, R; Ruel, N; Sarkodee-Adoo, C; Smith, E; Zain, J | 1 |
| Hanke, A; Lohse, P; Meissner, B; Rehe, K; Sauer, M; Sykora, KW; Welte, K; Zeidler, C | 1 |
| Alyea, E; Antin, JH; Attar, E; Ballen, KK; Cutler, C; Dey, BR; Haspel, R; Ho, V; Kao, G; Lee, S; Liney, D; McAfee, S; Soiffer, R; Spitzer, TR; Yeap, BY | 1 |
| Bertz, H; Bley, TA; Feuerhake, F; Finke, J; Mielke, S; Potthoff, K; Windfuhr, M | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| Bruno, C; Cappelli, B; Castagnola, E; Cuzzubbo, D; Dallorso, S; Dini, G; Faraci, M; Lanino, E; Micalizzi, C; Morreale, G; Rossi, A; Schiaffino, MC | 1 |
| Antolak, J; Chan, KW; Ha, CS; Kornguth, DG; Mahajan, A; Woo, S | 1 |
| Anagnostopoulos, A; Anderlini, P; Carrasco-Yalan, A; Champlin, RE; Couriel, D; de Lima, M; de Meis, E; Donato, M; Ghosh, S; Giralt, S; Hosing, C; Kebriaei, P; Khouri, I; Oran, B; Popat, U; Qazilbash, M; Saliba, R | 1 |
| Attarbaschi, A; Fritsch, G; Gadner, H; Lawitschka, A; Lion, T; Matthes-Martin, S; Minkov, M; Mittheisz, E; Steiner, M; Zoubek, A | 1 |
| Arbelaez, JE; Bacigalupo, A; Bregni, M; Carnevalli, E; Corradini, P; Davoli, M; De Fabritiis, P; Di Bartolomeo, P; Locasciulli, A; Majolino, I; Musso, M; Narni, F; Olivieri, A; Pogliani, L; Ruscio, C; Scimè, R; Selleri, C | 1 |
| Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
| Alousi, A; Anagnostopoulos, A; Anderlini, P; Carrasco-Yalan, A; Champlin, RE; Couriel, D; de Lima, M; Detry, MA; Giralt, S; Hosing, C; Kebriaei, P; Khouri, IF | 1 |
| Hardan, I; Herscovici, C; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R | 1 |
| Bureo, E; Diaz de Heredia, C; Gonzalez-Vicent, M; Maldonado, MS; Martinez, A; Muñoz, A; Olivé, T; Sastre, A | 1 |
| Bhatia, R; Chang, K; Forman, SJ; Kirschbaum, M; Kogut, N; Naing, A; Nakamura, R; O'Donnell, MR; Palmer, J; Pullarkat, V; Rodriguez, R; Slovak, ML; Spielberger, R; Stein, A; Tsai, N | 1 |
| Artz, AS; Daugherty, C; Godley, L; Huo, D; Larson, R; Odenike, OM; Pollyea, DA; Rich, E; Smith, SM; Stock, W; van Besien, K; Zhang, Y; Zimmerman, T | 1 |
| Alvarez, I; Arranz, R; Caballero, D; Canales, M; Cavet, J; Garcia-Conde, J; Goldstone, AH; Hunter, A; Linch, DC; Mackinnon, S; Mahendra, P; Milligan, D; Parker, A; Peggs, KS; Qian, W; Ribera, JM; Sanz, G; Sierra, J; Sureda, A; Thomson, K; Urbano-Ispizua, A | 1 |
| Anderlini, P; Andersson, BS; Caldera, Z; Champlin, RE; Chan, KW; Cook, JD; Couriel, D; de Lima, M; Giralt, S; Hosing, C; Jabbour, E; Kebriaei, P; Khouri, I; Martin, TG; McCormick, G; Patah, PA; Qazilbash, M; Shpall, EJ; Thall, PF; Wang, X | 1 |
| Barnes, Y; Bleesing, J; Davies, SM; Filipovich, AH; Hansen, MD; Hayashi, R; Jodele, S; Mehta, P; Shenoy, S | 1 |
| Kohno, A; Kuwatsuka, Y; Miyamura, K; Morishita, Y; Murata, M; Narimatsu, H; Sugimoto, K; Uchida, T; Watanabe, M | 1 |
| Acholonu, S; Anderlini, P; Andersson, B; Champlin, RE; Couriel, D; de Lima, M; Fayad, L; Giralt, SA; Hagemeister, F; Hosing, C; Khouri, IF; Munsell, MF; Pro, B; Qazilbash, MH; Romaguera, J; Saliba, R; Ueno, NT; Younes, A | 1 |
| Murata, M; Naoe, T; Narimatsu, H; Sugimoto, K; Terakura, S | 1 |
| Adachi, S; Kobayashi, C; Kojima, S; Kurosawa, H; Manabe, A; Nakahata, T; Nakazawa, Y; Nara, T; Ogawa, C; Ohtsuka, Y; Osugi, Y; Sako, M; Tokuyama, M; Yabe, H; Yabe, M; Yanagimachi, M | 1 |
| Atanackovic, D; Ayuk, F; Bacher, U; Bethge, W; Bokemeyer, C; Bornhäuser, M; Dierlamm, J; Gutierrez, NC; Hansen, T; Kröger, N; Liebisch, P; Miguel, JS; Nagler, A; Otterstetter, S; Penas, EM; Pérez-Simón, JA; San Miguel, J; Schilling, G; Schwerdtfeger, R; Shimoni, A; Simon-Perez, JA; Zabelina, T; Zander, A | 1 |
| Bertz, H; Finke, JM; Hahn, J; Holler, E; Ihorst, G; Marks, R; Potthoff, K; Spyridonidis, A | 1 |
| Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D | 1 |
| Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, RB; Korbling, M; Pierre, B; Roberson, S; Russell, JA; Shpall, EJ; Thall, PF; Wang, X | 1 |
| Bhatla, D; Bleesing, J; Crockett, M; Davies, SM; Filipovich, AH; Hansen, M; Harris, RE; Jodele, S; Jordan, M; Mehta, PA; Shenoy, S; Shoultz, L; Smolarek, T | 1 |
| Cupelli, L; de Fabritiis, P; Dentamaro, T; Giovannini, M; Niscola, P; Palumbo, R; Perrotti, AP; Piccioni, D; Scaramucci, L; Tendas, A | 1 |
| Gil, L; Komarnicki, M; Kozlowska-Skrzypczak, M; Mol, A; Poplawski, D; Styczynski, J | 1 |
| Benninghoff, U; Debatin, KM; Friedrich, W; Gatz, S; Hoenig, M; Schuetz, C; Schulz, A; Speth, F | 1 |
| Champlin, RE; Couriel, D; de Lima, M; de Souza, J; Giralt, S; Komanduri, KV; Oran, B; Patah, P; Rondon, G; Saliba, RM | 1 |
| Bloor, A; Chakraverty, R; Clark, F; Cook, G; Linch, DC; Mackinnon, S; Milligan, D; Morris, EC; Parker, A; Peggs, KS; Thomson, KJ; Yung, L | 1 |
| Barba, P; Briones, J; Brunet, S; Delgado, J; Martino, R; Moreno, E; Piñana, JL; Sierra, J; Sureda, A; Valcárcel, D; Vega, M | 1 |
| Flomenberg, N; Greipp, PR; Huff, CA; Lazarus, HM; Vesole, DH; Zhang, L | 1 |
| Karas, M; Koza, V; Steinerova, K; Vokurka, S | 1 |
| Cho, BS; Cho, SG; Chung, NG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Dishaw, LJ; Dorsey, MJ; Morrow, MR; Petrovic, A; Sleasman, JW | 1 |
| Imataki, O; Ishida, T; Kitanaka, A; Kubota, Y; Ohbayashi, Y; Ohnishi, H; Tanaka, T | 1 |
| Champlin, RE; de Lima, M; de Padua Silva, L; de Souza, JA; Efebera, Y; Hosing, C; Patah, P; Popat, U; Qazilbash, MH; Ribeiro, R; Rondon, G; Saliba, RM | 1 |
| Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL | 1 |
| Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC | 1 |
| Bornhäuser, M; Brand, R; de Witte, T; Gahrton, G; Heinzelmann, M; Kröger, N; Morris, C; Nagler, A; Niederwieser, D; Schilling, G; Schwerdtfeger, R; Shimoni, A; Zander, AR | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D | 1 |
| HANDA, H; KARASAWA, M; MATSUSHIMA, T; MAWATARI, M; MURAKAMI, H; NOJIMA, Y; OSAKI, Y; SAITOH, T; SEKIGAMI, T; TAHARA, K; TOYAMA, K; TSUKAMOTO, N; UCHIUMI, H; YOKOHAMA, A | 1 |
| Ansell, SM; Elliott, MA; Gastineau, DA; Hogan, WJ; Holtan, SG; Inwards, DJ; Johnston, PB; Lacy, MQ; Litzow, MR; Micallef, IN; Porrata, LF | 1 |
| Acholonu, S; Champlin, R; Dabaja, B; Donato, M; Duvic, M; Hosing, C; Khouri, I; Richmond, H; Singh, L; Wei, W | 1 |
| Chakraverty, R; Denovan, S; Fielding, AK; Hough, R; Kottaridis, PD; Linch, DC; Mackinnon, S; Mead, AJ; Mohamedbhai, S; Morris, EC; Orti, G; Peggs, KS; Thomson, KJ | 1 |
| Khouri, I; Tam, CS | 1 |
| Asano-Mori, Y; Ishiwata, K; Masuoka, K; Matsuno, N; Miyakoshi, S; Ohashi, K; Ota, Y; Takagi, S; Takahashi, K; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, H | 1 |
| Bloor, A; Chakraverty, R; Clark, A; Clark, R; Collin, M; Crawley, C; Fielding, A; Hale, G; Johnson, P; Kottaridis, P; Mackinnon, S; Milligan, D; Morris, E; Orti, G; Parker, A; Peggs, K; Pettengell, R; Pettitt, A; Roughton, M; Shen, J; Snowden, J; Thomson, K | 1 |
| Alyea, E; Antin, JH; Armand, P; Attar, E; Ballen, K; Boussiotis, VA; Brown, J; Cutler, C; Dey, BR; Herrera, M; Ho, V; Kao, G; Kim, HT; Koreth, J; Liney, D; McDonough, S; Reynolds, C; Ritz, J; Soiffer, R; Spitzer, T; Stevenson, K | 1 |
| Eto, T; Fukuda, T; Hagihara, M; Hatanaka, K; Iida, H; Kanda, Y; Kasai, M; Kawano, F; Maeda, Y; Masuoka, K; Mori, T; Murata, M; Nagafuji, K; Nakagawa, H; Nakamae, M; Nishiwaki, K; Shirafuji, N; Takahashi, S; Takaue, Y; Taniguchi, S; Taniwaki, M; Togami, K; Uchida, T; Ueda, Y; Utsunomiya, A; Wake, A; Waki, F; Yakushiji, K; Yakushijin, K; Yamashita, T | 1 |
| Dagis, A; Forman, S; Hitt, D; Naeem, H; Qian, D; Rosenthal, J; Stein, A; Thomas, SH; Wong, J | 1 |
| Chao, NJ; Chino, JP; Craciunescu, O; Folz, RJ; Horwitz, ME; Kelsey, CR; Marks, LB; Rizzieri, DA; Steffey, B | 1 |
| Choi, MK; Chung, CW; Hong, JY; Jang, JH; Kim, DH; Kim, HO; Kim, K; Kim, SJ; Kim, WS; Min, YH | 1 |
| Chen, R; Delioukina, M; Forman, S; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Rosenthal, J; Shen, J; Smith, E | 1 |
| Atsuta, Y; Imahashi, N; Ito, T; Kato, T; Miyamura, K; Morishita, Y; Murata, M; Naoe, T; Nishiwaki, S; Ohashi, H; Sawa, M; Suzuki, R; Terakura, S; Yasuda, T | 1 |
| Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J | 1 |
| Delioukina, M; Forman, S; Palmer, JM; Thomas, S; Tsai, N; Zain, J | 1 |
| Alousi, AM; Anderlini, P; Andersson, BS; Champlin, RE; de Lima, MJ; Giralt, SA; Hosing, C; Kebriaei, P; Khouri, IF; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Saliba, RM | 1 |
| Ashizawa, M; Kako, S; Kanda, Y; Kikuchi, M; Kimura, S; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sakamoto, K; Sato, M; Terasako, K; Wada, H; Yamazaki, R | 1 |
| Jungova, A; Karas, M; Koza, V; Svoboda, T; Vokurka, S | 1 |
| Horino, S; Matsuhashi, T; Minegishi, M; Niizuma, H; Onuma, M; Rikiishi, T; Sakamoto, O; Sasahara, Y; Tsuchiya, S; Uchiyama, T; Uematsu, M | 1 |
| Baxter-Lowe, LA; Bhatia, M; Bradley, MB; Cairo, MS; Della-Latta, P; Freedman, J; Garvin, JH; George, D; Geyer, MB; Harrison, L; Jacobson, JS; Moore, V; Morris, E; Satwani, P; Schwartz, J; van de Ven, C | 1 |
| Acholonu, S; Alousi, AM; Anderlini, P; Champlin, RE; Chancoco, C; Ciurea, S; Fanale, MA; Hosing, CM; Khouri, IF; Ledesma, C; Nieto, Y; Popat, UR; Saliba, RM; Shpall, EJ; Valverde, R; Younes, A | 1 |
| Abraham, A; Kasow, KA; Morales-Tirado, VM; Persons, DA; Riberdy, JM; Shurtleff, SA; Wichlan, D | 1 |
| Boudova, L; Jindra, P; Karas, M; Kazakov, D; Koza, V; Svoboda, T; Vokurka, S | 1 |
| Bruns, I; Czibere, A; Fenk, R; Galonska, L; Germing, U; Groten, A; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Weigelt, C; Zohren, F | 1 |
| Bassett, R; Champlin, RE; Chan, KW; Ciurea, SO; Couriel, DR; de Lima, M; Fernandez-Vina, M; Hamerschlak, N; Hosing, CM; Jones, RB; Karduss Aurueta, AJ; Kebriaei, P; McMannis, J; Nieto, Y; Petropoulos, D; Qazilbash, M; Rondon, G; Saliba, RM; Sharma, M; Shpall, EJ; Worth, LL | 1 |
| Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H | 1 |
| Adachi, S; Fujita, N; Ishii, E; Kanai, R; Nishi, M; Nishimura, R; Ohga, S; Okamura, T; Sato, E; Sawada, A; Suzuki, N; Yano, J; Yasumi, T; Yasutomo, K | 1 |
| Aisa, Y; Kato, J; Mori, T; Nakamura, Y; Nakazato, T; Okamoto, S; Shigematsu, N | 1 |
| Baurmann, H; Bethge, WA; Bornhauser, M; Bunjes, D; Dittmann, H; Faul, C; Federmann, B; Kanz, L; Stelljes, M; Trenschel, R; Vogel, W; von Harsdorf, S | 1 |
| Kato, J; Kikuchi, T; Kohashi, S; Mori, T; Okamoto, S; Ono, Y; Shimizu, T; Yamane, A | 1 |
| Alvarnas, J; Bhatia, R; Cai, JL; Chang, K; Chao, J; Forman, SJ; Maegawa, R; Nakamura, R; O'Donnell, MR; Palmer, JM; Parker, PM; Pullarkat, V; Senitzer, D; Snyder, DS; Stein, AS; Stiller, T; Thomas, SH; Wang, S | 1 |
| Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M | 1 |
| Alchalby, H; Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Fehse, B; Hansen, T; Heinzelmann, M; Klyuchnikov, E; Kröger, N; Schilling, G; Schwarz, S; Stübig, T; Wolschke, C; Zabelina, T; Zander, AR; Zeschke, S | 1 |
| DeCook, LJ; Hogan, WJ; Holtan, SG; Huneke, T; Johnson, ND; Litzow, MR; Patnaik, MM; Porrata, LF; Thoma, M; Wiegand, RA | 1 |
| Forman, SJ; Htut, M; Karanes, C; Krishnan, AY; Murata-Collins, J; Palmer, J; Rincon, A; Sahebi, F; Shen, Y; Somlo, G; Thomas, SH | 1 |
| Barba, P; Carreras, E; Fernández-Avilés, F; Garcia-Cadenas, I; López Corral, L; López-Anglada, L; Martino, R; Novelli, S; Pérez-Simón, JA; Piñana, JL; Rovira, M; Sierra, J; Valcárcel, D | 1 |
| Andersson, BS; Bayraktar, UD; Boulad, F; Castro-Malaspina, HR; Champlin, RE; Chen, J; Chiattone, A; de Lima, M; Giralt, S; Jakubowski, AA; Kernan, NA; Maloy, M; O'Reilly, RJ; Papadopoulos, EB; Rondon, G; Saliba, RM | 1 |
| Alsina, M; Anasetti, C; Baz, R; Jim, HS; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Pidala, J; Shain, K; Sullivan, D | 1 |
| Adams, RH; Betcher, JA; Dueck, AC; Fauble, VD; Khera, N; Klein, JL; Leis, JF; Noel, P; Reeder, CB; Slack, JL; Sproat, LO | 1 |
| Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D | 1 |
| Atsuta, Y; Goto, H; Inagaki, J; Inoue, M; Ishii, E; Kato, K; Kawa, K; Koike, K; Ohga, S; Okada, K; Sawada, A; Suzuki, N; Suzuki, R; Yabe, H; Yasutomo, K | 1 |
| Bashir, Q; Champlin, R; Ciurea, S; De Lima, M; Dinh, YT; Giralt, S; Hosing, CM; Jones, R; Kebriaei, P; Khan, H; Liu, P; Nieto, Y; Oran, B; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Rondon, G; Shah, JJ; Shah, N; Shpall, E; Thall, PF | 1 |
| Goi, K; Hara, T; Kamachi, Y; Kojima, S; Kumaki, S; Morio, T; Muramatsu, H; Sasahara, Y; Sugita, K; Takada, H; Tsuchiya, S; Urabe, T | 1 |
| Berkahn, L; Bryant, A; Cannell, P; Doocey, R; Fay, K; George, B; Hertzberg, M; Kalff, A; Kennedy, G; Moore, J; Nivison-Smith, I; Patil, S; Pillai, ES; Ritchie, D; Spearing, R; Spencer, A | 1 |
| Bajwa, RP; Rose, MJ; Woods, G | 1 |
| Abrams, S; Chen, GL; Hahn, T; Liu, H; McCarthy, PL; Ross, M; Zhang, Y | 1 |
| Agarwal, R; Ball, JB; Hutchinson, SK; Kharbanda, S; Lamb, LS; McKenna, DH; Smith, AR; Wagner, JE; Weinberg, KI | 1 |
| Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N | 1 |
| Ambrosetti, A; Attolico, I; Barzan, A; Benedetti, F; Bergui, L; Billio, A; Carlo-Stella, C; Chiarenza, A; Devizzi, L; Di Nicola, M; Di Raimondo, F; Gianni, AM; Gueli, A; Guidetti, A; Intermesoli, T; Magni, M; Matteucci, P; Montanari, M; Mulè, A; Olivieri, A; Parvis, G; Patti, C; Rambaldi, A; Scimè, R; Tarella, C; Trentin, L; Valagussa, P; Viero, P; Viviani, S | 1 |
| Bilmon, I; Bryant, A; Greenwood, M; Hertzberg, M; Kennedy, G; Moore, J; Nivison-Smith, I; Ritchie, D; Spencer, A | 1 |
| Blijlevens, NM; de Haan, AF; Donnelly, JP; Herbers, AH; van der Velden, WJ | 1 |
| Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY | 1 |
| Bleesing, JJ; Chandrakasan, S; Davies, SM; Filipovich, AH; Jordan, MB; Marsh, RA | 1 |
| Andreasson, B; Bacigalupo, A; Barosi, G; Boyer, M; Goldberg, JD; Gupta, V; Hoffman, R; Isola, L; Klisovic, RB; Marchioli, R; Mascarenhas, J; Miller, C; Najfeld, V; Orazi, A; Prchal, JT; Price, LS; Prosperini, G; Rambaldi, A; Rondelli, D; Scarano, M; Shore, TB; Silverman, LR; Vannucchi, AM; Weinberg, RS; Wetzler, M | 1 |
| Coiteux, V; de Berranger, E; Duhamel, A; Duléry, R; Gauthier, J; Gomez, E; Langlois, C; Magro, L; Terriou, L; Yakoub-Agha, I | 1 |
| Divoka, M; Faber, E; Indrak, K; Langova, K; Pikalova, Z; Raida, L; Rohon, P; Rusinakova, Z; Skoumalova, I; Szotkowska, R | 1 |
| Afanasyev, B; Baron, F; Deconinck, E; Jindra, P; Labopin, M; Mohty, M; Nagler, A; Peniket, A; Sanz, MA | 1 |
| Bleesing, JJ; Davies, SM; Filipovich, AH; Haines, HL; Hornung, L; Jordan, MB; Marsh, RA | 1 |
| Inagaki, J; Kakuda, H; Kudo, K; Kurosawa, H; Manabe, A; Ohtsuka, Y; Sakashita, K; Watanabe, K; Yabe, H; Yabe, M; Yoshida, N | 1 |
| Adachi, S; Atsuta, Y; Goto, H; Hasegawa, D; Inagaki, J; Inoue, M; Ishida, H; Kato, K; Kawa, K; Koh, K; Kudo, K; Okamoto, Y; Yabe, H | 1 |
| Araoka, H; Asano-Mori, Y; Ikebe, T; Ishiwata, K; Izutsu, K; Kon, A; Makino, S; Masuoka, K; Matsuno, N; Nakano, N; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A | 1 |
| Iida, H; Imahashi, N; Kasai, M; Kato, C; Kato, T; Kiyoi, H; Kohno, A; Kurahashi, S; Miyamura, K; Miyao, K; Murata, M; Naoe, T; Nishida, T; Ohashi, H; Ozawa, Y; Sakemura, R; Sawa, M; Terakura, S; Watamoto, K; Yokohata, E | 1 |
| Arthur, C; Fay, K; Gifford, G; Greenwood, M; Kerridge, I; Stevenson, W; Wong, K | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Yoon, JH | 1 |
| Davis, J; Haut, P; Hayashi, R; Kothari, A; Loechelt, BJ; Murray, L; Ngwube, A; Shenoy, S | 1 |
| Bellman, D; Bleesing, JJ; Chandra, S; Dandoy, C; Davies, SM; El-Bietar, J; Filipovich, AH; Gefen, A; Grimley, M; Jodele, S; Jordan, MB; Khandelwal, P; Kumar, AR; Leemhuis, T; Marsh, RA; Mehta, PA; Myers, KC; Rao, MB; Zhang, K | 1 |
| Broers, AE; Janssen, JJ; Raymakers, R; Slot, S; Smits, K; Te Boekhorst, PA; van de Donk, NW; Witte, BI; Zweegman, S | 1 |
| Ali, M; Chellapandian, D; Gassas, A; Krueger, J; Naqvi, A; Schechter, T; Weitzman, S | 1 |
| Jeon, M; Kang, YA; Kim, DY; Lee, JH; Lee, KH; Lee, YS; Seol, M | 1 |
| Iida, H; Kato, T; Kawashima, N; Kohno, A; Kusumoto, S; Kuwatsuka, Y; Miyamura, K; Miyao, K; Mizuta, S; Morishita, Y; Murata, M; Naito, K; Nakase, K; Nishida, T; Ozawa, Y; Sao, H; Sawa, M; Taji, H; Tsurumi, H | 1 |
| Fujisawa, S; Ishibashi, D; Ishigatsubo, Y; Kawasaki, R; Koharazawa, H; Matsumoto, K; Nakajima, Y; Tachibana, T; Tanaka, M; Yamamoto, E | 1 |
| Gergis, U; Mayer, S; Parmar, S; Patel, K; Shah, S; Shore, T; van Besien, K | 1 |
| Behfar, M; Faghihi-Kashani, S; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Hosseini, AS; Moin, M; Movahedi, M; Mozafari, M; Pourpak, Z | 1 |
| Bhargava, S; Chakrabarti, A; Chakrabarti, S; Chatterjee, S; Jaiswal, SR; O'Donnell, P; Ray, K | 1 |
| Davies, SM; Filipovich, AH; Jodele, S; Lane, A; Marsh, RA; Mehta, PA; Neumeier, L | 1 |
| Aoki, J; Fujii, E; Ishigatsubo, Y; Kanamori, H; Matsumoto, K; Tanaka, M; Yamamoto, E; Yamamoto, W | 1 |
| Ishiyama, K; Kawabata, H; Kitano, T; Kondo, T; Sugimoto, N; Takaori-Kondo, A; Takeda, J | 1 |
| Alchalby, H; Ayuk, F; Cassinat, B; Christopeit, M; Kröger, N; Peffault de Latour, R; Porcher, R; Robin, M; Sicre de Fontbrune, F; Socié, G; Wolschke, C; Zabelina, T | 1 |
| Alexandrova, IY; Grishina, GV; Kozlov, VA; Makarov, SV; Minaev, YL; Mishchenko, OV; Rossiev, VA; Semagina, OV | 1 |
| Alousi, AM; Anderlini, P; Champlin, RE; Fanale, MA; Hagemeister, FB; Hosing, CM; Khouri, IF; Ledesma, C; Neelapu, S; Nieto, Y; Oki, Y; Plair, T; Popat, UR; Romaguera, JE; Saliba, RM; Shpall, EJ; Younes, A | 1 |
| Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC | 1 |
| Chan, KW; Chaudhury, S; Douglas, D; Gilman, AL; Hale, GA; Haut, P; Hayashi, RJ; Kasow, KA; Madden, LM; Murray, LM; Pulsipher, MA; Shenoy, S | 1 |
| Adams, S; Allwood, Z; Amrolia, P; Chiesa, R; Lucchini, G; Qasim, W; Rao, K; Silva, J; Veys, P; Worth, A | 1 |
| Asano-Mori, Y; Ishiwata, K; Izutsu, K; Kageyama, K; Kaji, D; Makino, S; Masuoka, K; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A; Yuasa, M | 1 |
| Andou, T; Fujisawa, S; Hagihara, M; Ishii, Y; Itabashi, M; Koyama, S; Matsumoto, K; Motohashi, K; Numata, A; Yamamoto, W | 1 |
| Hogan, JJ; Weiss, BM | 1 |
| Katsanis, E; Kopp, LM; Pelayo-Katsanis, L; Sapp, LN; Whitney, K; Zeng, Y | 1 |
| Antin, JH; Armand, P; Caballero, D; Cabrero, M; Esquirol, A; Kekre, N; Lopez-Corral, L; Marquez-Malaver, FJ; Martino, R; Pérez-Simon, JA; Piñana, J; Soiffer, RJ; Solano, C; Terol, MJ | 1 |
| Choe, HK; Gergis, U; Mayer, SA; Nagar, H; Phillips, AA; Shore, TB; Smith, MJ; van Besien, K | 1 |
| Ikegame, K; Inoue, T; Ishii, S; Kaida, K; Kojima, H; Kusunoki, Y; Ogawa, H; Okada, M; Saji, H; Soma, T; Tamaki, H; Yoshihara, K; Yoshihara, S | 1 |
| Coelho, R; Flagg, A; Gonzalez, BE; Hanna, R; Harrington, S; Kusick, K; Ondrejka, S; Procop, GW; Stempak, LM; Zembillas, A | 1 |
| Chandra, S; Emoto, C; Fukuda, T; Khandelwal, P; Marsh, RA; Mehta, PA; Neumeier, L; Teusink-Cross, A; Vinks, AA | 1 |
| Bigley, V; Collin, M; Craddock, C; Dickinson, AM; Green, K; Jackson, G; Jardine, L; Mackinnon, S; Nagra, S; Nicolson, PLR; Pearce, K; Peggs, KS; Sellar, RS; Thomson, K | 1 |
| Alyea, EP; Bashey, A; Deeg, HJ; Devine, SM; Fernandez, HF; Geller, NL; Giralt, S; Hamadani, M; Horowitz, MM; Horwitz, ME; Le-Rademacher, J; Leifer, E; Logan, BR; Maziarz, RT; Mendizabal, AM; Pasquini, MC; Porter, DL; Scott, BL; Warlick, ED; Wu, J | 1 |
| Ashida, A; Ashida, T; Enomoto, A; Hamada, S; Matsunaga, K; Miki, H; Mukai, T; Torihata, S; Uchihashi, T; Yasumoto, M; Yasutake, N | 1 |
| Alousi, A; Burke, E; Cao, K; Champlin, R; Chen, J; de Lima, M; Hosing, C; Kaur, I; Kebriaei, P; Marin, D; Mehta, RS; Olson, A; Oran, B; Parmar, S; Popat, U; Rezvani, K; Saliba, RM; Shah, N; Shpall, EJ; Skerrett, D | 1 |
| Abraham, A; Cluster, A; Delgado, D; Hulbert, ML; Jacobsohn, D; Kukadiya, D; Murray, L; Shenoy, S | 1 |
| Barker, JN; Boulad, F; Castro-Malaspina, H; Fuller, K; Hilden, PD; Hsu, KC; Jakubowski, AA; Kernan, NA; Koehne, G; O'Reilly, RJ; Papadopoulos, EB; Perales, MA; Prockop, SE; Scaradavou, A; Spitzer, B; van den Brink, MR; Young, JW | 1 |
| Connolly, EC; Dhere, V; Edelman, S; Esiashvili, N; Graiser, M; Khan, MK; Langston, A; Switchenko, JM; Waller, EK | 1 |
| Aoki, J; Atsuta, Y; Eto, T; Fukuda, T; Ichinohe, T; Ishiyama, K; Iwato, K; Kahata, K; Kako, S; Kanamori, H; Kanda, Y; Kawamura, K; Kondo, T; Mizuta, S; Ozawa, Y; Sawa, M; Uchida, N; Yano, S | 1 |
| Bentz, M; Binnenhei, M; Bohl, SR; Bullinger, L; Bunjes, D; Döhner, H; Döhner, K; Drognitz, K; Kuchenbauer, F; Kündgen, L; Moulin, JC; Nguyen, TM; Ringhoffer, M; Schlenk, RF; Teleanu, V; von Harsdorf, S; Wais, V | 1 |
| Bruno, B; Chalandon, Y; Charbonnier, A; Coiteux, V; Simon, N; Souchet, L; Taque, S; Vincent, L; Yakoub-Agha, I | 1 |
| Avni, B; Grisariu, S; Hussein, F; Lokshin, E; NaserEddin, A; Oron, HC; Shadur, B; Stepensky, P; Zaidman, I | 1 |
| Fauble, V; Hogan, WJ; Jain, T; Khera, N; Kunze, KL; Leis, JF; Mesa, RA; Noel, P; Palmer, J; Partain, DK; Patnaik, MS; Roy, V; Slack, JL; Sproat, LZ; Temkit, M | 1 |
| Allen, CE; Andolina, JR; Baker, KS; Bollard, CM; Bryant, C; Burroughs, L; Connelly, J; Dawson, P; Eapen, M; Hanna, R; Kean, L; Marsh, R; Pai, SY; Pulsipher, MA; Ramirez, A; Roehrs, P; Schultz, KR; Shenoy, S; Stenger, EO; Talano, JA | 1 |
| Baker, L; Holder, K; Kanellopoulos, A; Kaparou, M; Kishore, B; Lovell, R; Nikolousis, E; Paneesha, S; Ryan, L; Suhr, J; Xenou, E | 1 |
| Alahdab, F; Almader-Douglas, D; Firwana, B; Jain, T; Palmer, J; Sonbol, MB | 1 |
| Hatsumi, N; Hoshino, T; Sakura, T; Takada, S | 1 |
| Aiyer, HM; Bansal, S; Bhakuni, P; Bhargava, S; Chakrabarti, S; Jaiswal, SR | 1 |
| Artz, A; Bishop, MR; Champlin, RE; Chen, J; Ciurea, SO; Gergis, U; Guarneri, D; Liu, H; Mayer, SA; Rondon, G; Shore, T; Srour, SA; Stock, W; van Besien, K | 1 |
| Arthur, C; Fay, K; Greenwood, M; Kerridge, I; Lindsay, J; Lwin, Y; Reid, C; Stevenson, W; Wong, K | 1 |
| Al-Atrash, G; Alousi, A; Bashir, Q; Betul, O; Bittencourt, MCB; Champlin, RE; Ciurea, SO; Daver, N; Hosing, C; Jabbour, E; Kantarjian, H; Kebriaei, P; Khouri, I; Kongtim, P; Konopleva, M; Masarova, L; Mehta, R; Olson, A; Perez, JMR; Popat, U; Ravandi, F; Saliba, RM; Short, N; Srour, SA | 1 |
| Bednarski, JJ; Bhatt, ST; Hente, M; Murray, L; Schulz, G; Shenoy, S; Slater, A | 1 |
| Fujita, N; Fukano, R; Fukuda, T; Hashii, Y; Inagaki, J; Inoue, M; Kato, K; Kobayashi, R; Maseki, N; Mitsui, T; Mori, T; Okada, K; Sato, A; Shimoyama, T; Shindo, M; Suzuki, R; Suzumiya, J; Tabuchi, K | 1 |
| Battiwalla, M; Brazauskas, R; Buchbinder, D; Cahoon, EK; Curtis, RE; Engels, EA; Flowers, ME; Herr, MM; Morton, LM; Shaw, BE; Tecca, HR; Tucker, MA | 1 |
| Alousi, A; Bashir, Q; Champlin, RE; Chen, J; Ciurea, SO; Daver, N; Hosing, C; Kongtim, P; Konopleva, M; Mehta, R; Olson, A; Oran, B; Popat, U; Rondon, G; Srour, S; Varma, A | 1 |
| Higashi, T; Hirosawa, M; Kominato, Y; Morimoto, H; Tanaka, A; Tsukada, J; Yamaguchi, T | 1 |
| Dreger, P; Hegenbart, U; Herfarth, K; Luft, T; Müller-Tidow, C; Radujkovic, A | 1 |
| Fujita, N; Fukano, R; Hashimoto, H; Kada, A; Kamei, M; Kobayashi, R; Koga, Y; Mitsui, T; Mori, T; Ohki, K; Osumi, T; Saito, AM; Sekimizu, M; Tanaka, F; Ueyama, J | 1 |
| Deguchi, T; Kato, M; Kiyotani, C; Matsumoto, K; Mizuno, T; Nakadate, H; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yoshimura, S | 1 |
| Akasaka, T; Atsuta, Y; Eto, T; Fukuda, T; Hidaka, M; Kanda, J; Kondo, T; Miyakoshi, S; Ota, S; Shiratori, S; Takami, A; Uchida, N; Yamashita, T; Yano, S | 1 |
| Al Malki, MM; Aldoss, I; Ali, H; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Nakamura, R; Pullarkat, V; Salhotra, A; Sandhu, K; Smith, E; Snyder, D; Stein, A; Tsai, NC | 1 |
| Atsuta, Y; Fujita, N; Goto, H; Inoue, M; Kato, K; Kawaguchi, H; Kobayashi, R; Koh, K; Kojima, S; Kudo, K; Miyamura, T; Okada, K; Okamoto, Y; Suzuki, R; Takahashi, Y; Watanabe, K; Yabe, H; Yabe, M; Yoshida, N | 1 |
| Baron, F; Hsu, J; Van Besien, K | 1 |
| Ahmed, S; Ahn, KW; Aljurf, M; Bacher, VU; Bredeson, C; Epperla, N; Farhadfar, N; Freytes, CO; Ganguly, S; Ghosh, N; Hamadani, M; Haverkos, B; Inwards, D; Kamble, RT; Khanal, M; Kharfan-Dabaja, MA; Lazarus, HM; Lekakis, L; Litovich, C; Murthy, HS; Nishihori, T; Ramakrishnan, P; Rizzieri, DA; Sureda, A; Yared, JA | 1 |
| Bertz, H; Duque-Afonso, J; Finke, J; Ihorst, G; Köhler, T; Marks, R; Müller-Quernheim, J; Wäsch, R; Waterhouse, M; Yücel, M; Zeiser, R | 1 |
| Brochstein, J; Sahdev, I; Stiles, J; Werther, N | 1 |
| Angelucci, E; Beauvais, D; Beelen, D; Bornhäuser, M; Castagna, L; Chevallier, P; Czerw, T; de Wreede, L; Finke, J; Hayden, P; Helbig, G; Hernández-Boluda, JC; Karakasis, D; Kröger, N; Maertens, J; Mauff, K; McLornan, D; Mear, JB; Mohty, M; Passweg, J; Polverelli, N; Reményi, P; Rifòn, J; Robin, M; Rubio, MT; Russo, D; Sirait, T; Vrhovac, R; Yakoub-Agha, I | 1 |
| Bansal, M; Bhargava, R; Chakraborty, S; Dua, V; Hamal, S; Sachdev, M | 1 |
| Aoki, Y; Ashiarai, M; Endo, A; Hiroki, H; Hoshino, A; Ichimura, T; Imai, K; Inoue, K; Inoue, M; Ishiwata, Y; Isoda, T; Kajiwara, M; Kamiya, T; Kanegane, H; Kawahara, Y; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Miyawaki, R; Mizutani, S; Morio, T; Nagasawa, M; Nishimura, A; Okano, T; Okawa, T; Ono, S; Ono, T; Takagi, M; Tanaka-Kubota, M; Tezuka, M; Tomizawa, D; Tomoda, T; Ueyama, J; Yamagishi, C; Yamashita, M; Yanagimachi, M; Yasuhara, M | 1 |
| Edahiro, T; Fujii, T; Fujino, K; Fukushima, N; Hirata, Y; Ichinohe, T; Kawase, T; Mino, T; Miyama, T; Morioka, T; Nagoshi, H; Nishizawa, M; Noma, M; Toishigawa, K; Yoshida, T | 1 |
| Ashida, T; Atsuta, Y; Fukuda, T; Hara, M; Ichinohe, T; Ikeda, T; Ishikawa, T; Kawakita, T; Maruyama, Y; Morishige, S; Shimomura, Y; Takada, S; Takanashi, M; Uchida, N; Wake, A; Yamamoto, H | 1 |
| Arai, Y; Atsuta, Y; Eto, T; Fukuda, T; Hirabayashi, S; Ichinohe, T; Ikegame, K; Kanda, J; Kawata, T; Kimura, T; Kondo, T; Marumo, A; Tabuchi, K; Tanaka, M; Uchida, N; Uozumi, R; Wake, A; Yanada, M; Yano, S | 1 |
| Atsuta, Y; Eto, T; Fukuda, T; Hara, M; Hirabayashi, S; Ichinohe, T; Kanda, Y; Kawakita, T; Kimura, T; Kondo, T; Maruyama, Y; Mizuno, S; Mukae, J; Nakano, N; Ota, S; Ozawa, Y; Shimomura, Y; Tanaka, M; Uchida, N; Yanada, M | 1 |
| Araqi Houssaini, L; Chiheb, S; Hali, F; Marnissi, F; Quessar, A | 1 |
| Agrawal, V; Ahn, KW; Aljurf, M; Bacher, U; Bashey, A; Beitinjaneh, A; Bredeson, C; Cerny, J; Chhabra, S; Copelan, E; Diaz, MA; Farhadfar, N; Farhan, S; Fretham, C; Gale, RP; Ganguly, S; Grunwald, MR; Hale, GA; Hashmi, S; Hildebrandt, GC; Jain, T; Kalaycio, M; Kharfan-Dabaja, MA; Lazarus, HM; Liesveld, JL; Litzow, M; Majhail, NS; Marks, DI; Murthy, HS; Nakamura, R; Nathan, S; Nishihori, T; Olsson, RF; Oran, B; Pawarode, A; Popat, U; Reshef, R; Rizzieri, D; Saber, W; Sabloff, M; Savani, BN; Scott, BL; Seo, S; Szer, J; van der Poel, M; Verdonck, LF; Weisdorf, D; Wirk, B; Yared, JA; Yves-Cahn, J | 1 |
| Adachi, H; Atsuta, Y; Doki, N; Igarashi, A; Ikegawa, S; Inamoto, K; Kaito, S; Kishida, Y; Kobayashi, T; Konishi, T; Konuma, R; Marumo, A; Mukae, J; Nagata, A; Nagata, R; Najima, Y; Noguchi, Y; Ohashi, K; Sakamaki, H; Toya, T; Wada, A; Yamada, Y | 1 |
| Abboud, R; Andolina, JR; DiPersio, JF; Eastburg, L; Fountaine, T; Huselton, E; Russler-Germain, DA | 1 |
| Alimoghaddam, K; Badalzadeh, M; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Mahdaviani, SA; Pourpak, Z; Setarehdan, SA; Souri, M; Tajik, S; Vaezi, M | 1 |
| Alkhateeb, HB; Barreto, EF; Bartoo, GT; Hogan, WJ; Kutzke, JL; Leung, N; Litzow, MR; Mangaonkar, AA; Mara, KC; Merten, JA; Pawlenty, AG; Shah, MV | 1 |
| Artz, AS; Aydogan, B; Bishop, MR; Hasan, Y; Kline, J; Kosuri, S; LaBelle, JL; Larson, RA; Liu, H; Partouche, J; Riedell, PA; Stock, W; Tran, MC; Wang, A; Weichselbaum, R; Yenice, K | 1 |
| Davini, M; de la Maza, M; Hanmod, S; Katsanis, E; Pariury, H; Proytcheva, M; Sapp, LN; Staples, K; Truscott, L | 1 |
| Beasley, M; Castleton, A; Chakraverty, R; Diez, P; Elhanied, M; Fielding, A; Gilleece, M; Hodgkinson, A; Jackson, A; Marks, DI; Mikhaeel, G; Olavarria, E | 1 |
14 review(s) available for fludarabine and melphalan
| Article | Year |
|---|---|
[Multiple myeloma and other plasma cell dyscrasias].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; Diagnosis, Differential; Heavy Chain Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Prognosis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 1999 |
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Podophyllotoxin; Radiotherapy, Adjuvant; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2001 |
Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Hypereosinophilic Syndrome; Male; Melphalan; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Bone Marrow; Busulfan; Cause of Death; Child; Child, Preschool; Cyclophosphamide; Europe; Female; Genetic Heterogeneity; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Infections; Inflammation; Male; Melphalan; Neutrophils; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
[Non-myeloablative therapy and allogeneic hematopoietic stem cell transplantation in hematologic malignancies].
Topics: Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Host vs Graft Reaction; Humans; Melphalan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytokines; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunotherapy, Adoptive; Kidney Neoplasms; Melphalan; Multicenter Studies as Topic; Nephrectomy; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Survival Analysis; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2002 |
[Mini-transplantation from cord blood].
Topics: Busulfan; Cyclophosphamide; Fetal Blood; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2003 |
Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Graft vs Tumor Effect; Humans; Immunologic Factors; Immunotherapy; Lymphocyte Transfusion; Lymphoma, Follicular; Melphalan; Methotrexate; Middle Aged; Multicenter Studies as Topic; Rituximab; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Vidarabine | 2007 |
Reduced intensity transplantation for congenital amegakaryocytic thrombocytopenia: report of a case and review of the literature.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Blood Platelets; Congenital Bone Marrow Failure Syndromes; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Melphalan; Methylprednisolone; Mucositis; Neutrophils; Thrombocytopenia; Transplantation Conditioning; Vidarabine | 2014 |
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine | 2016 |
Mycobacterium genavense-induced spindle cell pseudotumor in a pediatric hematopoietic stem cell transplant recipient: Case report and review of the literature.
Topics: Abdomen; Adolescent; Alemtuzumab; Antibiotic Prophylaxis; Antibiotics, Antitubercular; Antibodies, Monoclonal, Humanized; Bone Marrow Transplantation; Bronchoalveolar Lavage Fluid; Cyclosporine; Diabetes Mellitus, Type 1; Diarrhea; Genetic Diseases, X-Linked; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytes; Humans; Immune System Diseases; Immunosuppressive Agents; Lymph Nodes; Male; Melphalan; Mycobacterium Infections, Nontuberculous; Mycophenolic Acid; Nontuberculous Mycobacteria; Photopheresis; Polymerase Chain Reaction; Transplantation Conditioning; Vidarabine | 2017 |
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Melphalan; Obesity; Renal Insufficiency, Chronic; Societies, Medical; Surveys and Questionnaires; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis.
Topics: Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2019 |
A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review.
Topics: Adult; Child; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Conditioning; Vidarabine | 2022 |
82 trial(s) available for fludarabine and melphalan
| Article | Year |
|---|---|
Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fatal Outcome; Female; Humans; Ifosfamide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pilot Projects; Prednisolone; Prednisone; Remission Induction; Staining and Labeling; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Vidarabine; Vinca Alkaloids; Vincristine | 1995 |
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Microsatellite Repeats; Middle Aged; Nuclear Family; Polymerase Chain Reaction; Recurrence; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2000 |
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Melphalan; Pilot Projects; Transplantation Conditioning; Vidarabine | 2000 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine | 2000 |
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Topics: Acute Disease; Adenosine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2001 |
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Melphalan; Middle Aged; Survival Analysis; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Melphalan; Middle Aged; Primary Myelofibrosis; Splenomegaly; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Living Donors; Male; Melphalan; Middle Aged; Prognosis; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan.
Topics: Adult; Aged; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Renal Cell; Female; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Male; Melphalan; Middle Aged; Neoplasm Metastasis; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mycophenolic Acid; Opportunistic Infections; Premedication; Prospective Studies; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2004 |
Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Nervous System Diseases; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Diseases | 2004 |
Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Infections; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2005 |
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Topics: Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antilymphocyte Serum; Antineoplastic Agents; Cell Adhesion Molecules; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Leukemia; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Radioisotopes; Radiometry; Rhenium; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2005 |
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.
Topics: Adolescent; Child; Child, Preschool; Combined Modality Therapy; Diarrhea; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Mouth Mucosa; Stomatitis; Survival Rate; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2006 |
Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Myeloablative Agonists; Podophyllotoxin; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2006 |
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Living Donors; Male; Melphalan; Middle Aged; Myeloablative Agonists; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2006 |
High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2006 |
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.
Topics: Adult; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Risk Factors; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutropenia; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Child; Child, Preschool; Colitis; Endocrine System Diseases; Food Hypersensitivity; Forkhead Transcription Factors; Genes, X-Linked; Graft Survival; Humans; Ichthyosis, X-Linked; Immunologic Deficiency Syndromes; Infant; Leukocyte Count; Melphalan; Postoperative Complications; Reoperation; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
Topics: Abnormalities, Multiple; Adolescent; Bone Marrow Diseases; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Pilot Projects; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Double unrelated reduced-intensity umbilical cord blood transplantation in adults.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cord Blood Stem Cell Transplantation; Female; Graft Survival; Graft vs Host Disease; Histocompatibility Testing; Humans; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2007 |
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survivors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Melphalan; Methotrexate; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gemtuzumab; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Transplantation, Homologous; Vidarabine | 2008 |
Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Mucopolysaccharidosis I; Pilot Projects; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.
Topics: Cord Blood Stem Cell Transplantation; Female; Graft Survival; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Transplantation Conditioning; Treatment Failure; Vidarabine | 2008 |
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
Topics: Adult; Disease-Free Survival; Female; Follow-Up Studies; Hodgkin Disease; Hospitals, University; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bayes Theorem; Busulfan; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2008 |
Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Female; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Leukemia, Myeloid, Acute; Lymphocytes; Male; Melphalan; Middle Aged; Neoplastic Cells, Circulating; Transplantation Conditioning; Transplantation, Homologous; Tumor Burden; Vidarabine | 2009 |
A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.
Topics: Adult; Aged; Cyclophosphamide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Premedication; Reoperation; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2009 |
Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2010 |
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Melphalan; Methotrexate; Middle Aged; Mycosis Fungoides; Myeloablative Agonists; Recurrence; Sezary Syndrome; Tacrolimus; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis.
Topics: Aged; Busulfan; Cord Blood Stem Cell Transplantation; Feasibility Studies; Female; Graft Survival; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2010 |
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; CD52 Antigen; Female; Glycoproteins; Graft vs Host Disease; HLA Antigens; Humans; Male; Melphalan; Middle Aged; Siblings; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2010 |
Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lymph Nodes; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies.
Topics: Adult; Bone Marrow Transplantation; Chimerism; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Cutaneous; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Skin Neoplasms; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cord Blood Stem Cell Transplantation; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Melphalan; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2012 |
Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Dose-Response Relationship, Radiation; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Grading; Prognosis; Prospective Studies; Radioimmunotherapy; Radiopharmaceuticals; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Yttrium Radioisotopes | 2012 |
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2013 |
Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan.
Topics: Adolescent; Allografts; Antilymphocyte Serum; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Infant; Japan; Lymphohistiocytosis, Hemophagocytic; Male; Melphalan; Myeloablative Agonists; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2013 |
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
Topics: Adolescent; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; beta-Thalassemia; Child; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Male; Melphalan; Mesenchymal Stem Cell Transplantation; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Unrelated Donors; Vidarabine | 2014 |
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Prospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine | 2014 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
Topics: Adult; Aged; Analysis of Variance; Antilymphocyte Serum; Blood Donors; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Janus Kinase 2; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Mutation; Primary Myelofibrosis; Prospective Studies; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2014 |
Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
Topics: Acute Disease; Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Melphalan; Myeloablative Agonists; Neutropenia; Prospective Studies; Risk; Siblings; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Prognosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2015 |
Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study
Topics: Adolescent; Adult; Allografts; Antilymphocyte Serum; Child; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Male; Melphalan; Prospective Studies; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine | 2016 |
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.
Topics: Aged; Allografts; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Hematologic Neoplasms; Humans; Male; Melphalan; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Middle Aged; Neutrophils; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
Topics: Alemtuzumab; Anemia, Sickle Cell; Calcineurin Inhibitors; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Hydroxyurea; Male; Melphalan; Mycophenolic Acid; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2017 |
Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.
Topics: Adolescent; Adult; Alemtuzumab; Antineoplastic Agents; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Melphalan; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
Topics: Adult; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Enzyme Inhibitors; Female; Graft vs Host Disease; Haplotypes; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neutrophils; Recovery of Function; Retrospective Studies; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2019 |
A single-center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease.
Topics: Alemtuzumab; Child; Child, Preschool; Follow-Up Studies; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Infant; Melphalan; Myeloablative Agonists; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission.
Topics: Aged; Allografts; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Female; Follow-Up Studies; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Vidarabine; Viral Load; Whole-Body Irradiation | 2020 |
A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large-Cell, Anaplastic; Melphalan; Transplantation Conditioning; Vidarabine | 2020 |
Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study.
Topics: Adolescent; Alemtuzumab; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Prognosis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2020 |
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EB
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Organ Size; Primary Myelofibrosis; Registries; Retrospective Studies; Spleen; Splenectomy; Survival Rate; Vidarabine | 2021 |
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Neoplasm Recurrence, Local | 2023 |
ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.
Topics: Acute Disease; Adult; Alemtuzumab; Clinical Trials, Phase II as Topic; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Whole-Body Irradiation | 2023 |
161 other study(ies) available for fludarabine and melphalan
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Melphalan; Middle Aged; Tumor Cells, Cultured; Vidarabine | 1997 |
Fludarabine-based preparative protocol for unrelated donor cord blood transplantation in children: successful engraftment with minimal toxicity.
Topics: Adolescent; Child; Fetal Blood; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 1999 |
Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenograstim; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nuclear Family; Psoriasis; Recombinant Proteins; T-Lymphocyte Subsets; Transplantation Chimera; Vidarabine | 2001 |
Acute left ventricular failure following melphalan and fludarabine conditioning.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Homologous; Ventricular Dysfunction, Left; Vidarabine | 2001 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Infections; Life Tables; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Spain; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; United Kingdom; Vidarabine | 2002 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Adult; Aged; Aged, 80 and over; Biological Transport; Carrier Proteins; Cell Survival; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes; Male; Melphalan; Membrane Transport Proteins; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tumor Cells, Cultured; Vidarabine | 2003 |
Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Graft Survival; Histiocytosis, Non-Langerhans-Cell; Humans; Infant; Melphalan; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cytomegalovirus; Cytomegalovirus Infections; Humans; Incidence; Melphalan; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Activation; Whole-Body Irradiation | 2003 |
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2004 |
Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Drug Resistance, Neoplasm; Female; Graft vs Tumor Effect; Humans; Melphalan; Ovarian Neoplasms; Vidarabine | 2004 |
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.
Topics: Antineoplastic Agents, Alkylating; Graft Rejection; Granulocyte Precursor Cells; Hematologic Diseases; Humans; Immunosuppressive Agents; Melphalan; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2004 |
High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cladribine; Cyclophosphamide; Cytarabine; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Idarubicin; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Melphalan; Prednisolone; Survival Analysis; Vidarabine; Vincristine | 2004 |
Conditioning regimen of melphalan, fludarabine and total body irradiation in unmanipulated HLA haploidentical stem cell transplantation based on feto-maternal tolerance.
Topics: Adult; Antineoplastic Agents, Alkylating; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Topics: Adult; Antigens, CD34; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Cell Fractionation; Cohort Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Opportunistic Infections; Pneumonia, Bacterial; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Five-month marrow aplasia in a child with refractory acute myeloid leukemia: successful management with continuous granulocyte support and reduced-intensity conditioning followed by matched unrelated bone marrow transplantation.
Topics: Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Female; Graft vs Host Disease; Granulocytes; Humans; Leukemia, Myelomonocytic, Acute; Melphalan; Neoplasm Recurrence, Local; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Agents; Disease-Free Survival; Graft vs Host Disease; Humans; Immunophenotyping; Melphalan; Multiple Myeloma; Proportional Hazards Models; Receptors, Immunologic; Receptors, KIR; Recurrence; Risk; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.
Topics: Female; Graft Survival; Graft vs Host Disease; Histiocytosis, Langerhans-Cell; Humans; Infant; Langerhans Cells; Male; Melphalan; Prognosis; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Costs and Cost Analysis; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Living Donors; Melphalan; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
[Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more].
Topics: Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
Topics: Adult; Amyloidosis; Diarrhea; Drug Therapy, Combination; Heart Diseases; Humans; Hypotension; Japan; Kidney Diseases; Male; Melphalan; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.
Topics: Adult; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Etoposide; Family; Graft vs Host Disease; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Magnetic Resonance Imaging; Male; Melphalan; Methotrexate; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2006 |
[Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Preschool; Cyclosporine; Graft vs Host Disease; Humans; Infant; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tissue Donors; Transplantation Conditioning; Vidarabine | 2006 |
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug Induced Liver Injury; Cholangitis; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Hematologic Diseases; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunosuppressive Agents; Incidence; Infant, Newborn; Liver Diseases; Liver Function Tests; Male; Melphalan; Middle Aged; Postoperative Complications; Risk Factors; Tacrolimus; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Infections; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclosporine; Demyelinating Diseases; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Assessment; Stem Cell Transplantation; Vidarabine | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
Allogeneic bone marrow transplantation for Pearson's syndrome.
Topics: Antifungal Agents; Antilymphocyte Serum; Antineoplastic Agents; Aspergillosis, Allergic Bronchopulmonary; Base Sequence; Bone Marrow Transplantation; DNA, Mitochondrial; Electron Transport; Female; Genetic Diseases, Inborn; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Leukemia, Myeloid; Melphalan; Mitochondrial Diseases; Myeloablative Agonists; Sequence Deletion; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Vidarabine | 2007 |
Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation.
Topics: Child; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lung; Male; Melphalan; Myeloablative Agonists; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Etoposide; Female; Graft Survival; Histiocytosis, Langerhans-Cell; Humans; Infant; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Melphalan; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vinblastine | 2007 |
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Stem Cell Transplantation; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortal
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Topics: Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Living Donors; Lymphocyte Depletion; Male; Melphalan; Multiple Organ Failure; Postoperative Complications; Reoperation; Retrospective Studies; Spain; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Wiskott-Aldrich Syndrome | 2007 |
Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Topics: Adult; Aged; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Potential role of a mismatched HLA-specific CTL clone developed pre-transplant in graft rejection following cord blood transplantation.
Topics: Clone Cells; Cord Blood Stem Cell Transplantation; Electroporation; Female; Graft Rejection; Histocompatibility Testing; HLA Antigens; HLA-A Antigens; HLA-B Antigens; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Leukemia, Myelomonocytic, Acute; Male; Melphalan; Middle Aged; Polymerase Chain Reaction; Receptors, Antigen, T-Cell; T-Lymphocytes, Cytotoxic; Transfection; Transplantation Chimera; Vidarabine | 2008 |
A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
Topics: Administration, Oral; Busulfan; Child; Child, Preschool; Female; History, Ancient; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Juvenile; Male; Melphalan; Pilot Projects; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome.
Topics: Abnormalities, Multiple; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft vs Host Disease; Humans; Male; Melphalan; Pancreatic Diseases; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2008 |
Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma.
Topics: Aged; Combined Modality Therapy; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Renal Dialysis; Transplantation Conditioning; Vidarabine | 2009 |
Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Carmustine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Neutropenia; Prospective Studies; Risk Factors; Rituximab; Vidarabine; Young Adult | 2009 |
Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Chimerism; Cyclophosphamide; Follow-Up Studies; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Kaplan-Meier Estimate; Male; Melphalan; Postoperative Complications; Pulmonary Aspergillosis; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult | 2009 |
Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cyclosporine; Female; Glomerular Filtration Rate; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Premedication; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2009 |
Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Prospective Studies; Risk Factors; Stomatitis; Transplantation Conditioning; Vidarabine; Young Adult | 2009 |
FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Autoimmune Diseases; Bone Marrow Transplantation; Forkhead Transcription Factors; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin E; Infant; Interleukin-7 Receptor alpha Subunit; Male; Melphalan; T-Lymphocytes, Regulatory; Transplantation Conditioning; Vidarabine; X-Linked Combined Immunodeficiency Diseases | 2009 |
Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen.
Topics: Adolescent; Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Kidney Injury; Adult; Aged; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2009 |
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reoperation; Retrospective Studies; Risk; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.
Topics: Female; Graft vs Host Disease; Humans; Janus Kinase 2; Melphalan; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2009 |
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Chronic Disease; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Living Donors; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.
Topics: Adult; Aged; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine | 2011 |
Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.
Topics: Adult; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Humans; Longitudinal Studies; Lymphocyte Count; Male; Melphalan; Multivariate Analysis; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2011 |
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
Topics: Acute Disease; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lung; Male; Melphalan; Middle Aged; Pneumonia; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Topics: Adult; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recurrence; Reoperation; Republic of Korea; Retrospective Studies; Salvage Therapy; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vidarabine | 2010 |
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT.
Topics: Adult; Aged; Cryotherapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Successful cord blood transplantation with reduced-intensity conditioning for childhood cerebral X-linked adrenoleukodystrophy at advanced and early stages.
Topics: Adrenoleukodystrophy; Brain; Child; Cord Blood Stem Cell Transplantation; Humans; Male; Melphalan; Myeloablative Agonists; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2012 |
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.
Topics: Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Genetic Diseases, Inborn; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Melphalan; Myeloablative Agonists; Neoplasms; Neutrophils; Recombinant Proteins; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2011 |
Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Cell Survival; Forkhead Transcription Factors; Genetic Diseases, X-Linked; Graft Enhancement, Immunologic; Graft Survival; Humans; Immunologic Deficiency Syndromes; Infant; Interleukin-2 Receptor alpha Subunit; Lymphocyte Depletion; Male; Melphalan; Point Mutation; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thiotepa; Thymus Gland; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Significant oral graft-versus-host disease after allogeneic stem cell transplantation with the FLU/MEL conditioning regimen.
Topics: Acute Disease; Adult; Aged; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Mouth Diseases; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine | 2011 |
Reduced-intensity conditioning in unrelated donor cord blood transplantation for familial hemophagocytic lymphohistiocytosis.
Topics: Blood Component Transfusion; Blood Donors; Child, Preschool; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Infant; Infant, Newborn; Japan; Lymphohistiocytosis, Hemophagocytic; Male; Melphalan; Reoperation; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2012 |
[Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].
Topics: Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2012 |
Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma.
Topics: Adult; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.
Topics: Adult; Aged; Chemoprevention; Dose-Response Relationship, Drug; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Sirolimus; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Topics: Adult; Cytogenetic Analysis; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prognosis; Prospective Studies; Remission Induction; Translocation, Genetic; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocytes; Male; Melphalan; Middle Aged; Monocytes; Prognosis; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2013 |
Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Living Donors; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2013 |
Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.
Topics: Adult; Aged; Blood Platelets; Female; Ferritins; Follow-Up Studies; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutrophils; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Remission Induction; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant
Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2013 |
B-cell function after unrelated umbilical cord blood transplantation using a minimal-intensity conditioning regimen in patients with X-SCID.
Topics: Antineoplastic Agents; B-Lymphocytes; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; HLA Antigens; Humans; Immunoglobulins; Infant; Male; Melphalan; Survival Rate; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; X-Linked Combined Immunodeficiency Diseases | 2013 |
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Australia; Bone Marrow Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Myeloablative Agonists; New Zealand; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Female; Graft vs Host Disease; Humans; Male; Melphalan; Methotrexate; Middle Aged; Vidarabine; Young Adult | 2014 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Outcomes following second allogeneic haematopoietic transplants using fludarabine-melphalan conditioning.
Topics: Adult; Aged; Allografts; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients.
Topics: Adult; Aged; Bacteremia; C-Reactive Protein; Citrulline; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mucositis; Myeloablative Agonists; Neutropenia; Prospective Studies; Transplantation Conditioning; Vidarabine | 2014 |
Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Infant; Intracellular Signaling Peptides and Proteins; Lymphoproliferative Disorders; Male; Melphalan; Mutation; Myeloablative Agonists; Prognosis; Retrospective Studies; Signaling Lymphocytic Activation Molecule Associated Protein; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2014 |
Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Chimerism; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Lymphoproliferative Disorders; Male; Melphalan; Mucopolysaccharidoses; Myeloablative Agonists; Retrospective Studies; Severe Combined Immunodeficiency; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Leukemia, Myelomonocytic, Juvenile; Male; Melphalan; Retreatment; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Japan; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2015 |
I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Hematologic Diseases; Humans; Male; Melphalan; Middle Aged; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2015 |
Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Chimerism; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Predictive Value of Tests; Prospective Studies; Recurrence; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2015 |
Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies.
Topics: Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chimerism; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2015 |
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calreticulin; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease Progression; Female; Graft Survival; Humans; Janus Kinase 2; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutrophils; Peripheral Blood Stem Cell Transplantation; Polycythemia Vera; Primary Myelofibrosis; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2015 |
Successful Allogeneic Hematopoietic Stem Cell Transplantation in XIAP Deficiency Using Reduced-Intensity Conditioning.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Child, Preschool; Genetic Diseases, X-Linked; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Male; Melphalan; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies.
Topics: Aged; Aged, 80 and over; Allografts; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
Successful Engraftment and Durable Graft-versus-host Disease Control with Haploidentical Peripheral Blood and a Short-term Conditioning Regimen for Primary Graft Failure.
Topics: Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2015 |
Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
Topics: Administration, Intravenous; Adult; Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal, Humanized; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2016 |
Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocytes; Melphalan; Prospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; C-Reactive Protein; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2016 |
Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Blood Platelets; Cord Blood Stem Cell Transplantation; Feasibility Studies; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neutrophils; Retrospective Studies; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2016 |
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Topics: Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Recurrence; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
[The role and place of high-dose immunosuppressive therapy and autologous transplantation of hematopoietic stem cells for autoimmune diseases].
Topics: Adult; Age Factors; Antilymphocyte Serum; Arthritis, Rheumatoid; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Melphalan; Multiple Sclerosis; Patient Acuity; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2016 |
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
Topics: Adult; Brentuximab Vedotin; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lung Diseases; Male; Melphalan; Middle Aged; Nausea; Remission Induction; Salvage Therapy; Skin Diseases; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2016 |
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing.
Topics: Adolescent; Adult; Aged; Area Under Curve; Busulfan; Female; Humans; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders.
Topics: Adolescent; Adult; Alemtuzumab; Bone Marrow Transplantation; Child; Child, Preschool; Female; Follow-Up Studies; Graft Survival; Hemoglobinopathies; Humans; Male; Melphalan; Myeloablative Agonists; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen.
Topics: Cell Lineage; Chimerism; Disease-Free Survival; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunologic Deficiency Syndromes; Infant; Infant, Newborn; Melphalan; Stem Cell Transplantation; Stem Cells; Vidarabine | 2016 |
A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies.
Topics: Adult; Aged; Busulfan; Female; Graft Survival; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis.
Topics: Adult; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
Alternative Donor Hematopoietic Cell Transplantation Conditioned With Myeloablative Busulfan, Fludarabine, and Melphalan is Well Tolerated and Effective Against High-risk Myeloid Malignancies.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid; Male; Melphalan; Myeloablative Agonists; Myeloproliferative Disorders; Remission Induction; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies.
Topics: Adult; Aged; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Radiation Dosage; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Spousal hematopoietic stem cell transplantation.
Topics: Adult; Allografts; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fatal Outcome; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Leukemia; Male; Melphalan; Middle Aged; Radiotherapy Dosage; Recurrence; Spouses; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2017 |
Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antineoplastic Agents, Immunological; Child; Child, Preschool; Graft vs Host Disease; Half-Life; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Count; Melphalan; Prospective Studies; Transplantation Conditioning; Vidarabine | 2017 |
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts.
Topics: Adult; Aged; Alemtuzumab; Allografts; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2017 |
Influences of FLU/BU and FLU/MEL on incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients.
Topics: Adult; Aged; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2017 |
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Melphalan; Middle Aged; Myelodysplastic Syndromes; Rabbits; Risk Assessment; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
Topics: Adult; Age Factors; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Patient Selection; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2018 |
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
Topics: Aged; Aged, 80 and over; Busulfan; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2017 |
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Staging; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2018 |
Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Melphalan; Myeloablative Agonists; Osteopetrosis; Prognosis; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2018 |
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2019 |
Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia.
Topics: Adult; Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Transplantation Conditioning; Vidarabine | 2018 |
Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.
Topics: Adult; Allografts; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
Targeting CD28-CD86 Pathway for Refractory Myeloma Through CTLA4Ig-Based Reduced-Intensity Conditioning and Donor Lymphocyte Infusions After Haploidentical Transplantation.
Topics: Abatacept; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-2 Antigen; CD28 Antigens; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation | 2019 |
Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Conditioning; Vidarabine | 2020 |
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation.
Topics: Adult; Aged; Bone Marrow; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Proportional Hazards Models; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2019 |
Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large-Cell, Anaplastic; Male; Melphalan; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2019 |
Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Busulfan; Case-Control Studies; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Karnofsky Performance Status; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Staging; Risk Factors; Skin; Skin Neoplasms; Tissue Donors; Transplantation Conditioning; Ultraviolet Rays; Vidarabine; Whole-Body Irradiation; Young Adult | 2020 |
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
Topics: Age Factors; Aged; Antineoplastic Agents; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2020 |
High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Calcineurin Inhibitors; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms, Second Primary; Proportional Hazards Models; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2020 |
Successful Umbilical Cord Blood Transplantation With Reduced-intensity Conditioning for Acute Myeloid Leukemia in a Child With Shwachman-Diamond Syndrome.
Topics: Antineoplastic Agents, Alkylating; Child; Cytarabine; Female; Fetal Blood; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Melphalan; Myeloablative Agonists; Shwachman-Diamond Syndrome; Transplantation Conditioning; Vidarabine | 2021 |
Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2020 |
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
Topics: Aged; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine | 2020 |
Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide.
Topics: Anemia, Aplastic; Bone Marrow Transplantation; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Conditioning; Vidarabine | 2020 |
Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation?
Topics: Busulfan; Humans; Leukemia, Myeloid, Acute; Melphalan; Transplantation Conditioning; Vidarabine | 2020 |
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
Topics: Allografts; Busulfan; Cohort Studies; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Melphalan; Myeloablative Agonists; Recurrence; Registries; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2020 |
Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2021 |
Haploidentical Stem Cell Transplant With Post-transplant Cyclophosphamide for Chediak-Higashi Syndrome: A Very Rare Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chediak-Higashi Syndrome; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Prognosis; Transplantation Conditioning; Vidarabine | 2021 |
Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
Topics: Busulfan; Child, Preschool; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Leukocyte Count; Male; Melphalan; Primary Immunodeficiency Diseases; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2021 |
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2021 |
Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
Topics: Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Propensity Score; Transplantation Conditioning; Vidarabine | 2021 |
Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT.
Topics: Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Nomograms; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2021 |
[Cutaneous complications following hematopoietic stem cell transplantation].
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Candidiasis; Chickenpox; Child; Chronic Disease; Dermatomycoses; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Herpes Genitalis; Humans; Induction Chemotherapy; Malassezia; Male; Melphalan; Middle Aged; Morocco; Prospective Studies; Skin Diseases; Skin Diseases, Infectious; Vidarabine; Young Adult | 2021 |
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.
Topics: Aged; Busulfan; Graft vs Host Disease; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Vidarabine | 2021 |
Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2022 |
Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide.
Topics: Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning.
Topics: Creatinine; Graft vs Host Disease; Humans; Iothalamic Acid; Melphalan; Retrospective Studies; Vidarabine | 2022 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Myelodysplastic Syndromes; Retrospective Studies; Siblings; Transplantation Conditioning; Young Adult | 2023 |